JPWO2006038656A1 - アレルギー抑制剤 - Google Patents
アレルギー抑制剤 Download PDFInfo
- Publication number
- JPWO2006038656A1 JPWO2006038656A1 JP2006539318A JP2006539318A JPWO2006038656A1 JP WO2006038656 A1 JPWO2006038656 A1 JP WO2006038656A1 JP 2006539318 A JP2006539318 A JP 2006539318A JP 2006539318 A JP2006539318 A JP 2006539318A JP WO2006038656 A1 JPWO2006038656 A1 JP WO2006038656A1
- Authority
- JP
- Japan
- Prior art keywords
- chrysin
- composition
- disease
- cells
- ige
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 70
- 230000007815 allergy Effects 0.000 title claims abstract description 59
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 46
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 claims abstract description 210
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 claims abstract description 103
- 235000015838 chrysin Nutrition 0.000 claims abstract description 103
- 229940043370 chrysin Drugs 0.000 claims abstract description 103
- 108010073816 IgE Receptors Proteins 0.000 claims abstract description 68
- 102000009438 IgE Receptors Human genes 0.000 claims abstract description 68
- 239000000203 mixture Substances 0.000 claims abstract description 62
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims abstract description 46
- 201000010099 disease Diseases 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 25
- 229960001340 histamine Drugs 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 23
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims abstract description 17
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000008714 apigenin Nutrition 0.000 claims abstract description 17
- 229940117893 apigenin Drugs 0.000 claims abstract description 17
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 238000012261 overproduction Methods 0.000 claims abstract description 9
- 229940119155 Histamine release inhibitor Drugs 0.000 claims abstract description 7
- 239000003301 histamine release inhibitor Substances 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 26
- 239000000043 antiallergic agent Substances 0.000 abstract description 7
- 230000001164 bioregulatory effect Effects 0.000 abstract description 2
- 235000012041 food component Nutrition 0.000 abstract description 2
- 239000005417 food ingredient Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 61
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
- 102000004388 Interleukin-4 Human genes 0.000 description 21
- 239000012528 membrane Substances 0.000 description 21
- 239000000872 buffer Substances 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 20
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 19
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 17
- 210000003651 basophil Anatomy 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000013566 allergen Substances 0.000 description 12
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 12
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 235000013824 polyphenols Nutrition 0.000 description 10
- -1 quercetin glycosides Chemical class 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 description 9
- 101710128966 High affinity immunoglobulin epsilon receptor subunit alpha Proteins 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 9
- 230000003266 anti-allergic effect Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 150000008442 polyphenolic compounds Chemical class 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 108020004635 Complementary DNA Proteins 0.000 description 8
- 238000010804 cDNA synthesis Methods 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 210000003630 histaminocyte Anatomy 0.000 description 8
- 235000012907 honey Nutrition 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 230000008105 immune reaction Effects 0.000 description 7
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 206010012438 Dermatitis atopic Diseases 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 101100293276 Caenorhabditis elegans cra-1 gene Proteins 0.000 description 4
- 208000004262 Food Hypersensitivity Diseases 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010039085 Rhinitis allergic Diseases 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 201000010105 allergic rhinitis Diseases 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 235000020932 food allergy Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000012133 immunoprecipitate Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 210000003519 mature b lymphocyte Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 3
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010082169 Chemokine CCL17 Proteins 0.000 description 3
- 108010083675 Chemokine CCL27 Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 235000004347 Perilla Nutrition 0.000 description 3
- 244000124853 Perilla frutescens Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 102000036693 Thrombopoietin Human genes 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 3
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 3
- 235000009498 luteolin Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 2
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 150000001765 catechin Chemical class 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- YQHMWTPYORBCMF-ZZXKWVIFSA-N 2',4,4',6'-tetrahydroxychalcone Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-ZZXKWVIFSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- SCZVLDHREVKTSH-UHFFFAOYSA-N 4',5,7-trihydroxy-3'-methoxyflavone Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 SCZVLDHREVKTSH-UHFFFAOYSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 206010001742 Allergy to animal Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- KMOUJOKENFFTPU-UHFFFAOYSA-N Apigenin-7-glucosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-UHFFFAOYSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010083702 Chemokine CCL21 Proteins 0.000 description 1
- 102000006435 Chemokine CCL21 Human genes 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
- 101000978374 Mus musculus C-C motif chemokine 12 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101100434648 Petromyzon marinus SDS-1 gene Proteins 0.000 description 1
- GPLOTACQBREROW-UHFFFAOYSA-N Phlegmanol A-acetat Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC1=2)C=C(O)C(=O)C1=C(O)C(O)=CC=2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GPLOTACQBREROW-UHFFFAOYSA-N 0.000 description 1
- VGEREEWJJVICBM-UHFFFAOYSA-N Phloretin Natural products C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 1
- FGUBFGWYEYFGRK-HNNXBMFYSA-N Pinocembrin Natural products Cc1cc(C)c2C(=O)C[C@H](Oc2c1)c3ccccc3 FGUBFGWYEYFGRK-HNNXBMFYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- YPWHZCPMOQGCDQ-UHFFFAOYSA-N Populnin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 YPWHZCPMOQGCDQ-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- KMJPKUVSXFVQGZ-WQLSNUALSA-N [(2r,3r)-5,7-dihydroxy-2-[3,4,5-trihydroxy-6-oxo-1-[(2r,3r)-3,5,7-trihydroxy-3,4-dihydro-2h-chromen-2-yl]benzo[7]annulen-8-yl]-3,4-dihydro-2h-chromen-3-yl] 3,4,5-trihydroxybenzoate Chemical compound O([C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(=O)C(O)=C2C(O)=C(O)C=C(C2=C1)[C@H]1OC2=CC(O)=CC(O)=C2C[C@H]1O)C(=O)C1=CC(O)=C(O)C(O)=C1 KMJPKUVSXFVQGZ-WQLSNUALSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002592 antimutagenic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- KMOUJOKENFFTPU-QNDFHXLGSA-N apigenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-QNDFHXLGSA-N 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- UOSZQIQUCYTISS-UHFFFAOYSA-N chrysoeriol Natural products C1=C(O)C(C)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 UOSZQIQUCYTISS-UHFFFAOYSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- QKUSRAKPUWQSJS-UHFFFAOYSA-N diazanium 3-ethyl-2H-1,3-benzothiazole-6-sulfonate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)C1=CC=C2N(CC)CSC2=C1.[O-]S(=O)(=O)C1=CC=C2N(CC)CSC2=C1 QKUSRAKPUWQSJS-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 210000000350 mc(t) Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 201000005299 metal allergy Diseases 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003000 phloroglucinols Chemical class 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- URFCJEUYXNAHFI-ZDUSSCGKSA-N pinocembrin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=CC=C1 URFCJEUYXNAHFI-ZDUSSCGKSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N quercetin Natural products C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- FYIJLTSMNXUNLT-RXRHLBNPSA-N strictinin Natural products O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@H]2OC(=O)c3c(c(O)c(O)c(O)c3)-c3c(O)c(O)c(O)cc3C(=O)OC[C@@H]2O1)c1cc(O)c(O)c(O)c1 FYIJLTSMNXUNLT-RXRHLBNPSA-N 0.000 description 1
- FYIJLTSMNXUNLT-CXQFPWCTSA-N strictinin Chemical compound O([C@@H]1O[C@@H]2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]2[C@H](O)[C@H]1O)C(=O)C1=CC(O)=C(O)C(O)=C1 FYIJLTSMNXUNLT-CXQFPWCTSA-N 0.000 description 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- FJYGFTHLNNSVPY-BBXLVSEPSA-N theaflavin digallate Chemical compound C1=C([C@@H]2[C@@H](CC3=C(O)C=C(O)C=C3O2)O)C=C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(=O)C2=C1C([C@H]1OC3=CC(O)=CC(O)=C3C[C@H]1O)=CC(O)=C2OC(=O)C1=CC(O)=C(O)C(O)=C1 FJYGFTHLNNSVPY-BBXLVSEPSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical class OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- PZYFJWVGRGEWGO-UHFFFAOYSA-N trisodium;hydrogen peroxide;trioxido(oxo)vanadium Chemical compound [Na+].[Na+].[Na+].OO.OO.OO.[O-][V]([O-])([O-])=O PZYFJWVGRGEWGO-UHFFFAOYSA-N 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
1) クリシンを含むヒスタミン放出阻害剤;
2) クリシンを含む組成物であって、IgE産生に関連する疾患又は状態を処置するための(より詳細には、IL-4誘導性IgE重鎖胚型転写に関連する疾患又は状態を処置するための、そしてSTAT6リン酸化に関連する疾患又は状態を処置するための)組成物;
3) クリシンを含む組成物であって、高親和性IgE受容体に関連する疾患又は状態を処置するための(より詳細には、細胞表面上の高親和性IgE受容体に関連する疾患又は状態を処置するための、高親和性IgE受容体を構成するα鎖又はγ鎖に関連する疾患又は状態を処置するための、そして高親和性IgE受容体の転写に関連する疾患又は状態を処置するための)組成物;及び
4) クリシンを含む組成物であって、IL-4の過剰産生に関連する疾患又は状態を処置するための組成物。
5) アレルギー抑制剤、ヒスタミン放出阻害剤、IgE産生に関連する疾患若しくは状態を処置するための組成物、高親和性IgE受容体に関連する疾患若しくは状態を処置するための組成物、又はIL-4の過剰産生に関連する疾患若しくは状態を処置するための組成物の製造における、クリシンの使用;並びに
6) アレルギーに関連する疾患若しくは状態、ヒスタミン放出に関連する疾患若しくは状態、IgE産生に関連する疾患若しくは状態、高親和性IgE受容体に関連する疾患若しくは状態、又はIL-4の過剰産生に関連する疾患若しくは状態を処置するための方法であって、そのような処置を必要とする哺乳動物に対して、処置上有効量のクリシンを投与することを含む、前記方法。
1.目的
われわれの体は免疫反応により体外から侵入する異物の攻撃から守られているが、時として免疫反応はわれわれの体に対して傷害的に作用する。このような免疫機能に基づく傷害反応はアレルギーと呼ばれるが、近年のアレルギー患者数の増加及び症状の重篤化が著しい。国民の約1/3は花粉症、アレルギー性鼻炎、気管支喘息、アトピー性皮膚炎など、なんらかの形でアレルギー疾患に罹患しているといわれるほどである。生体内で起こる免疫反応には、抗体が関与する液性免疫と抗体が関与しない細胞性免疫があり、I型からIII型アレルギー反応は前者に、IV型アレルギー反応は後者に属する。花粉アレルギーなどの環境アレルギーはI型アレルギーにより発症するが、食物アレルギーではI型アレルギーに加え、II型及びIV型アレルギーの関与が疑われている。アレルゲンが生体内に侵入すると、アレルゲン特異的抗体の産生が誘導されるが、I型アレルギーの発症には特にIgE型の抗体が重要な役割を果たす。B細胞により産生されたIgEはマスト細胞や好塩基球の細胞膜上に存在する高親和性IgE受容体に結合する。そこに、アレルゲン物質が再び侵入してマスト細胞や好塩基球上のIgEを架橋すると、ヒスタミン等のメディエーターが放出され、アレルギーの発症に至る。
クリシン:
クリシンはSigma Chemical Co.(St. Louis, MO)より購入した。クリシンはdimethyl sulfoxide (DMSO)に溶解し、エタノールで10% DMSOとなるように希釈した。
ヒト成熟B細胞株DND39は5% FBS (Intergen) 添加RPMI 1640培地(Nissui) にて、37℃、水蒸気飽和した 5% CO2条件下で継代、維持した。RPMI 1640培地は、100 U/mL ペニシリン (Meiji Seika)、100 mg/mL ストレプトマイシン(Meiji Seika)、12.5 mM NaHCO3(Wako)、10 mM HEPES(Wako)を添加したものを用いた。
DND39細胞を2 x 105 cells/mLに調整し、IL-4 (25 U/mL)及び各濃度のクリシン存在下で48時間培養した。1 x 107 cellsを超えない細胞培養液を15 mLポリプロピレン製の遠心管に回収し、300 x gで遠心、上清除去し、PBSにて一度洗浄した。遠心、上清除去した細胞はRNaseによるRNA の分解を極力抑えるため、次の操作まで氷中で保管した。この細胞にTrizol(Invitrogen, Carlxbad, CA) を1 mL加え、ピペッティングにより塊が見えなくなるまで良く懸濁し、懸濁液を1.5 mLチューブに移して、このチューブを5分間静置した。200μLのクロロホルム(和光純薬)を加えて強く攪拌し、室温で3分間静置したのちに12.000 x g、15分間遠心した。上層450μLを別の1.5 mL チューブに移し、500μL のイソプロパノ-ル(和光純薬)を加えて強く攪拌した後、室温で10分間静置した。12.000 x g で 10分間遠心した後、チューブを傾けて上清を除去し、1 mLの75%エタノールを加えて強く攪拌後、12.000 x gで5分間遠心して上清を除いた。回収したtotal RNAはDEPC水 10μLに溶解し、100倍希釈したものを分光光度計Ultrospec3000(Pharmacia Biotech, Piscataway, NJ)を用いてRNA濃度を測定した。
10 x PCR buffer (1μL)、
25 mM MgCl2 (1μL)、
2.5 mM dNTPs (0.8μL)、
Taq DNA polymerase (0.1μL)、
20μM sense primer (0.5μL)、
20μM anti-sense primer (0.5μL)、
上記で調製した cDNA (1μL)、
dH2O (5.1μL)。
εGT-F : 5'-Agg CTC CAC TgC CCg gCA Cag AAA T-3'、
εGT-R : 5'-Acg gAg gTg gCA TTg gAg ggA Atg T-3'、
G3PDH-F : 5'-gCT Cag ACA CCA Tgg ggA Agg T-3'、
G3PDH-R : 5'-gTg gTg Cag gAg gCA TTg CTg A-3'。
1回目;20 x SSC (5mL)+10% SDS (1mL) : 30min : 60℃、
2回目;20 x SSC (2mL)+10% SDS (1mL) : 30min : 60℃、
3回目;20 x SSC (1mL)+10% SDS (1mL) : 60min : 60℃。
DND39 細胞を2 x 106 cells/mLとなるように調整し、IL-4 (100 U/ml)及び各濃度のクリシンを添加し、30 分間処理して細胞を溶解した。細胞溶解物を抗STAT6抗体を用いて免疫沈降し、免疫沈降物を8% SDS-PAGEに供し、ニトロセルロース膜にブロット後、抗チロシンリン酸化抗体 (PY20) にてリン酸化STAT6検出した。
結果を図1及び図2に示した。クリシンは濃度依存的にεGTの発現を抑制し、またSTAT6のリン酸化を抑制した。クリシンはεGT発現をSTAT6のリン酸化レベルで阻害することにより、IgEの産生を根本的に抑制することが分かった。
1.目的:
アレルゲンが生体内に侵入すると、アレルゲン特異的抗体の産生が誘導されるが、即時型アレルギーの発症には特にIgE型の抗体が重要な役割を果たす。B細胞により産生されたIgEは肥満細胞及び好塩基球の細胞膜上に存在する高親和性IgE受容体に結合する。そこに、アレルゲン物質が再び侵入して肥満細胞上のIgEを架橋すると、ヒスタミンやロイコトリエン等のメディエーターが放出され、アレルギーの発症に至る。
細胞及び細胞培養:
細胞の培養にはRPMI 1640(Nissui, Japan)培地に、100 U/mLペニシリン(Meiji Pharmaceutical Company, Tokyo, Japan)、100mg/mLストレプトマイシン(Meiji Pharmaceutical Company)、12.5mM NaHCO3(Wako Pure Chemical Industries, Osaka, Japan)、10mM HEPES(Wako Pure Chemical Industries)を添加したものを基本培地として使用した。Fetal bovine serum(FBS)はBio Source Internationalより購入し、基本培地に5 - 10%となるように添加して用いた。本実験に用いたヒト好塩基球様細胞株KU812はJapan Collection of Research Bioresources(JCRB)より分譲されたもので、5 - 10% FBS添加RPMI 1640培地で37(C、5%炭酸ガス加湿下で継代、維持した。
クリシン(Sigma)はdimethyl sulfoxide (DMSO)に溶解し、エタノールで10% DMSOとなるように希釈した。
KU812細胞(1 x 106 cells/mL)を、DMSOに溶解したクリシンを添加したRPMI 1640培地で0 - 24時間培養した。DMSOのみを添加して培養した系をコントロールとした。培養後、細胞を回収し、抗ヒトFcεRI α鎖マウスモノクローナル抗体CRA-1(Kyokuto Pharmaceutical)を10μg/mLとなるように添加した5% FBS-PBS中で4(C、40 - 60分間インキュベートした。ネガティブコントロールとしてマウスコントロールIgG2b抗体(DAKO)を10μg/mLで用いた。その後、氷冷PBSで一度洗浄し、抗マウスIgG2b FITC標識抗体(Protos Immunoresearch)を10μg/mLとなるよう添加した5% FBS-PBS中で4(C、40 - 60分間インキュベートした。インキュベート後、PBSで洗浄し、PBSで再懸濁した細胞懸濁液をフローサイトメトリー解析に共した。フローサイトメトリー解析にはFACSCalibur(Becton Dickinson, Sunnyvale, CA)を使用した。なお、二次抗体反応以降は遮光条件で行い、解析まで氷上で保存した。
KU812細胞(1 x 106 cells/mL)を、クリシンを添加したRPMI 1640培地で6時間無血清培養を行った。培養後、細胞を一度PBSで洗浄後、Lysis buffer(組成:50mM Tris-HCl pH 7.5 、1% Triton X-100、150mM NaCl、1mM EDTA、50mM NaF 、30mM Na4P2O7、1mMPMSF、2μg/mL aprotinin、1mM pervanadate)を加え、4(Cで30分間振とうして溶解した。その後、12,000 x g、4(Cで10分間遠心し不溶物を沈殿させ、上清を回収してタンパク定量を行いそれぞれのサンプルのタンパク濃度が等濃度となるようにLysis bufferで希釈し、細胞溶解サンプルとした。
クリシンを添加したRPMI 1640培地でKU812細胞(1 x 106 cells/mL)を6時間無血清培養した。培養後、細胞を一度PBSで洗浄後、1 x 107個の細胞に対し1mLのTrizol(Invitrogen)を加えて速やかに懸濁して完全に溶解させた。室温で5分間静置後、0.2mLのChloroformを添加して激しく転倒攪拌した。室温で3分間静置後、12,000 x g、4(Cで15分間遠心後、上清を450μL回収し0.5mLの2-Propanolを添加して激しく転倒攪拌し、室温で10分間静置した。12,000 x g、4(Cで10分間遠心後、上清を除去し、1mLの75% Ethanolで沈殿をリンスした。12,000 x g、4(Cで5分間遠心後、上清をできる限り除去し、沈殿したRNAを10 - 20μLのDEPC水に溶解させた。水で50倍希釈した全RNA濃度を260nmの波長を用いて測定し、全てのサンプルの全RNA濃度が10μgになるように0.1%ジエチルピロカーボネート(DEPC)水(Sigma)で希釈を行った。
ヒトFcεRI α鎖センスプライマー:5'-CTTAGGATGTGGGTTCAGAAGT-3'、
アンチセンスプライマー:5'-GACAGTGGAGAATACAAATGTCA-3'。
ヒトFcεRI γ鎖センスプライマー:5'-TAGGGCCAGCTGGTGTTAATGGCA-3'、
アンチセンスプライマー:5'-GATGATTCCAGCAGTGGTCTTGCT-3'。
ヒトG3PDHセンスプライマー:5'-GCTCAGACACCATGGGGAAGGT-3'、
アンチセンスプライマー: 5'-GTGGTGCAGGAGGCATTGCTGA-3'。
結果を図3〜5に示した。クリシンはFcεRIの発現をmRNAレベルで抑制した。FcεRI発現を抑制することから、クリシンは、IgE/FcεRI複合体により惹起される脱顆粒反応を抑制し、後に生じるアレルギー炎症等を軽減しうることが分かった。
投与サンプル:
0.4 mg/mLのクリシンを200μLずつ、又はコントロールとして1% DMSO 1% EtOHを200μLずつを、各群(n=8)に、次項の投与スケジュールにしたがって投与した。
1週間予備摂食(MF食)させた5週齢のC57BL/6N雄マウスに、2週間にわたり、2日に1回サンプルを投与した。(計7回投与。合計投与量は、一匹あたり0.56mg(28mg/kg)。)
IL-4応答性の検討:
屠殺後のマウスの脾臓から回収した脾臓リンパ球を2 x 107 cells/mLに調整し、リポ多糖(lipopolysaccharide,LPS) (25μg/mL)又は LPS + IL-4(500 U/mL)にて30分間刺激した。その後細胞を溶解し、抗STAT6 抗体を用いた免疫沈降及びimmunoblot法によりリン酸化STAT6を検出することで、IL-4に対する応答性を検討した。
結果を図6に示した。クリシンを投与した系では、コントロールに比較し、LPS + IL-4刺激によるSTAT6のリン酸化を抑制した。
1. 方法:
ドナーの前腕肘部より静脈採血を行い、Lymphocyte Separation Medium(ICN Biomedical Inc.)により末梢血リンパ球を、Percoll(Amersham Biosciences)密度勾配遠心法により末梢血好塩基球を分離精製した。好塩基球(1 x 106 cells/mL)を、25 M クリシン若しくは溶媒であるジメチルスルフォキシド(DMSO)を添加した5% FCS-RPMI 1640培地で24時間培養後、RNAを抽出し、FcεRI α、γ鎖のmRNA発現レベルを、実施例1と同様に、RT-PCR法により検討した。
結果を図7に示した。クリシンは、いずれのドナーにおいても、末梢血好塩基球のFcεRIα及びγ鎖のmRNA発現レベルを減少させたが、特に、FcεRIα鎖の発現を強力に低下させた。ヒト末梢血細胞に対してもクリシンが高親和性IgE受容体FcεRIの発現を強力に抑制することが分かった。
1. 方法:
ヒト好塩基球細胞株KU812細胞(5 x 105 cells/mL)を25 μM クリシン添加1 mM CaCl2含有Tyrode buffer(137 mM NaCl、2.7 mM KCl、1.8 mM CaCl2、1.1 mM MgCl2、11.9 mM NaHCO3、0.4 mM NaH2PO4、pH 7.4)で37℃、20分間インキュベートし、さらに5 μM A23187(Sigma Chemical Co.)を加えて37℃、20分間インキュベートした。インキュベート後、氷中に5分間静置して反応を停止させ、上清1 mLを回収した。また、細胞内ヒスタミン蓄積量を測定するサンプルについては、細胞を300 x gで5分間遠心した後超音波破砕を約1分間行い、12,000 x gで5分間遠心後上清を1 mL回収した。次に、アルカリ条件下でヒスタミンをo-Phtaldehyde(Wako)により蛍光化して定量を行うため、部分抽出を行った。サンプル1 mL、Tyrode buffer 1 mL、NaCl 0.75-0.78 gそして5 N NaOH 0.5 mLを混合して攪拌した。さらに、5 mLのn-Butanol : Chloroform = 3 : 2の混合液(v/v)を加えてボルテックスミキサーで攪拌後、300 x gで5分間遠心した。次に上層を4 mL採取し、0.1 N HCl 1.5 mLとn-Heputan 2 mLを加えてボルテックスミキサーで攪拌後、300 x gで5分間遠心した。1 N NaOH 0.15 mLに下層1 mL添加し、0.2% OPA(Methanolに溶解して調製)0.1 mLを加えて蛍光化学反応を開始した。室温で5分間反応させた後、0.5 N H2SO4 0.14 mLを加えて反応を停止させた。蛍光強度は蛍光光度計RF-1500を用いて励起波長360 nm、蛍光波長450 nmで測定を行った。
結果を図8に示した。
1. 方法:
8週齢BALB/c雄マウスをAIN-93M摂食群(Control群)と0.025% クリシン添加AIN-93M摂食群に分け、3週間各食餌を与えた後、両群ともAIN-93M食を2週間摂食させた。1匹あたり5 g/dayとなるように摂食させ、自由飲水で飼育した。
結果を下表に示した。
1. 方法:
実施例6と同様に採血を行い、血清中の32種類(6Ckine, CTACK, Eotaxin, G-CSF, GM-CSF, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-12p70, IL-13, IL-17, IFN-γ, KC, Leptin, MCP-1, MCP-5, MIP-1α, MIP-2, MIP-3β, RANTES, SCF, sTNFRI, TARC, TIMP-1, TNF-α, Tpo, VEGF)をRay BioTM Mouse Cytokine Array(Ray Biotech, Inc.)を用いて検出した。
結果を下表に示した。なお、表中の数値は非摂食群の値を1とした場合の相対値である。
1. 方法:
KU812細胞(5 x 105 cells/mL)を、クリシン(0, 1 , 5, 10 μM)及びアピゲニン(Aldrich Chem. Co. (St. Louis, MO) から購入)(0, 1, 5, 10 μM)を添加した5%ウシ胎児血清含有RPMI 1640培地で24時間培養を行った。培養後、フローサイトメトリー解析により細胞表面FcεRI発現レベルを測定した(実験方法は0047参照)。
結果を下表に示した。
Claims (10)
- クリシンを含む、アレルギー抑制剤。
- クリシンを含む、ヒスタミン放出阻害剤。
- IgE産生に関連する疾患又は状態を処置するための、クリシンを含む組成物。
- 高親和性IgE受容体に関連する疾患又は状態を処置するための、クリシンを含む組成物。
- IL-4の過剰産生に関連する疾患又は状態を処置するための、クリシンを含む組成物。
- 1日当たりの経口投与量又は摂取量中に、1.68g以上のクリシンを含む、医薬又は食品用組成物。
- さらにアピゲニンを含む、請求項1に記載のアレルギー抑制剤、請求項2に記載のヒスタミン阻害剤、又は請求項3〜5のいずれか1項に記載の組成物。
- クリシン及びアピゲニンを含む、医薬、食品又は化粧用組成物。
- アレルギー抑制剤、ヒスタミン放出阻害剤、IgE産生に関連する疾患若しくは状態を処置するための組成物、高親和性IgE受容体に関連する疾患若しくは状態を処置するための組成物、又はIL-4の過剰産生に関連する疾患若しくは状態を処置するための組成物の製造における、クリシンの使用。
- アレルギーに関連する疾患若しくは状態、ヒスタミン放出に関連する疾患若しくは状態、IgE産生に関連する疾患若しくは状態、高親和性IgE受容体に関連する疾患若しくは状態、又はIL-4の過剰産生に関連する疾患若しくは状態を処置するための方法であって、そのような処置を必要とする哺乳動物に対して、処置上有効量のクリシンを投与することを含む、前記方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004292500 | 2004-10-05 | ||
JP2004292500 | 2004-10-05 | ||
PCT/JP2005/018451 WO2006038656A1 (ja) | 2004-10-05 | 2005-10-05 | アレルギー抑制剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2006038656A1 true JPWO2006038656A1 (ja) | 2008-05-15 |
Family
ID=36142728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006539318A Pending JPWO2006038656A1 (ja) | 2004-10-05 | 2005-10-05 | アレルギー抑制剤 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20080262080A1 (ja) |
JP (1) | JPWO2006038656A1 (ja) |
WO (1) | WO2006038656A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2906716B1 (fr) * | 2006-10-06 | 2013-05-17 | Clarins Lab | Utilisation d'une composition cosmetique pour le soin des peaux grasses. |
US20090276436A1 (en) * | 2008-04-30 | 2009-11-05 | Nokia Corporation | Method, apparatus, and computer program product for providing service invitations |
US20130273026A1 (en) * | 2012-04-12 | 2013-10-17 | Integrative Enzymatics, Inc. | Composition and method for modulating inflammatory molecules with amylase |
JP5976025B2 (ja) * | 2014-02-28 | 2016-08-23 | 株式会社Aob慧央グループ | ヒアルロン酸合成促進剤の製造方法、ヒアルロン酸合成促進剤、HAS2mRNA発現促進剤の製造方法及びHAS2mRNA発現促進剤 |
CN111166739B (zh) * | 2020-02-18 | 2021-04-20 | 西安交通大学 | 柯因在制备抗类过敏药物中的应用 |
JP2023524312A (ja) * | 2020-05-08 | 2023-06-09 | グレータルズ オーストラリア プロプライアタリー リミテッド | 線維化疾患及び炎症性疾患の予防及び治療のための組成物及び方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07118151A (ja) * | 1993-10-21 | 1995-05-09 | Kureha Chem Ind Co Ltd | アトピー性皮膚炎治療剤 |
JPH10510803A (ja) * | 1994-12-13 | 1998-10-20 | バイヤースドルフ・アクチエンゲゼルシヤフト | 化粧品及び皮膚科学的調製物中への、免疫調節剤又は免疫保護剤としてのフラボノイドの使用 |
JP2001114686A (ja) * | 1999-10-15 | 2001-04-24 | Sunstar Inc | Th2サイトカイン発現抑制剤 |
JP2004161664A (ja) * | 2002-11-13 | 2004-06-10 | Fancl Corp | プロポリス組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2128293C (en) * | 1993-12-06 | 2002-09-03 | Masayuki Tanabe | Fruit polyphenols and medicinal compositions containing them |
JP2000086510A (ja) * | 1998-09-16 | 2000-03-28 | Oriza Yuka Kk | ヒスタミン遊離抑制剤 |
JP3694733B2 (ja) * | 2000-06-29 | 2005-09-14 | 独立行政法人農業・生物系特定産業技術研究機構 | 抗アレルギー剤 |
-
2005
- 2005-10-05 JP JP2006539318A patent/JPWO2006038656A1/ja active Pending
- 2005-10-05 WO PCT/JP2005/018451 patent/WO2006038656A1/ja active Application Filing
- 2005-10-05 US US11/664,622 patent/US20080262080A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07118151A (ja) * | 1993-10-21 | 1995-05-09 | Kureha Chem Ind Co Ltd | アトピー性皮膚炎治療剤 |
JPH10510803A (ja) * | 1994-12-13 | 1998-10-20 | バイヤースドルフ・アクチエンゲゼルシヤフト | 化粧品及び皮膚科学的調製物中への、免疫調節剤又は免疫保護剤としてのフラボノイドの使用 |
JP2001114686A (ja) * | 1999-10-15 | 2001-04-24 | Sunstar Inc | Th2サイトカイン発現抑制剤 |
JP2004161664A (ja) * | 2002-11-13 | 2004-06-10 | Fancl Corp | プロポリス組成物 |
Also Published As
Publication number | Publication date |
---|---|
WO2006038656A1 (ja) | 2006-04-13 |
US20080262080A1 (en) | 2008-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rosenkranz et al. | Induction of regulatory T cells in Th1-/Th17-driven experimental autoimmune encephalomyelitis by zinc administration | |
Li et al. | Naringenin inhibits dendritic cell maturation and has therapeutic effects in a murine model of collagen-induced arthritis | |
Ren et al. | Total flavonoids from sea buckthorn ameliorates lipopolysaccharide/cigarette smoke‐induced airway inflammation | |
RU2423139C2 (ru) | КОМПОЗИЦИИ, СОДЕРЖАЩИЕ Actinidia, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
JP6638092B2 (ja) | ピロロキノリンキノン、その誘導体及び/又は塩の乾燥症候群における使用ならびに医薬組成物 | |
Nair et al. | Grape seed extract proanthocyanidins downregulate HIV-1 entry coreceptors, CCR2b, CCR3 and CCR5 gene expression by normal peripheral blood mononuclear cells | |
Iwaki et al. | Tryptanthrin inhibits Th2 development, and IgE-mediated degranulation and IL-4 production by rat basophilic leukemia RBL-2H3 cells | |
JPWO2006038656A1 (ja) | アレルギー抑制剤 | |
JP2012516842A (ja) | 代謝症候群の抑制のためのスファランサス・インディクスおよびガルシニア・マンゴスターナ由来の組成物 | |
JP7060500B2 (ja) | 薬学的組成物の製造方法、医薬部外品組成物の製造方法、飼料組成物の製造方法、及び、飲用水添加剤の製造方法 | |
Lee et al. | Ursodeoxycholic acid attenuates experimental autoimmune arthritis by targeting Th17 and inducing pAMPK and transcriptional corepressor SMILE | |
Chen et al. | Dexmedetomidine ameliorates renal ischemia reperfusion-mediated activation of the NLRP3 inflammasome in alveolar macrophages | |
JP6081025B2 (ja) | モノアセチルジアシルグリセロール化合物を有効成分として含有する喘息の予防または治療用組成物 | |
US11359011B2 (en) | Treatment and prevention of cardiovascular disease | |
JP5804592B2 (ja) | 抗アレルギーのための医薬品組成物 | |
JP6000206B2 (ja) | 抗アレルギー用経口組成物 | |
US20220291237A1 (en) | Gene Expression Inflammatory Age and Its Uses | |
JP2007228855A (ja) | 抗肥満剤のスクリーニング方法 | |
KR102446154B1 (ko) | Stat3 억제제를 유효성분으로 포함하는 면역질환 또는 염증성질환 예방 또는 치료용 약학적 조성물 | |
KR20050103185A (ko) | 출혈과 관련된 신경계 손상의 치료 방법 | |
JP7321435B2 (ja) | N-アセチル又はn-アシルアミノ酸を含むアトピー又は痒み症治療用組成物 | |
Sun et al. | Zileuton ameliorates neuronal ferroptosis and functional recovery after spinal cord injury | |
JP6113325B2 (ja) | 抗アレルギー用経口組成物 | |
JP2020063194A (ja) | マクロファージの機能低下抑制剤 | |
KR102450560B1 (ko) | 혈갈 추출물을 유효성분으로 포함하는 혈액암의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080930 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20080930 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20081111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090116 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090615 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090714 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20091002 |